Global assessment of psychosocial functioning and predictors of outcome in schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 1, 2011, Pages 62-68

  Stefanopoulou, Evgenia ^a   Lafuente, Antonio Romero ^b   Fonseca, Andres Saez ^c   Keegan, Shaun ^c   Vishnick, Celia ^d   Huxley, Adam ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Waterfront Building   (United Kingdom)

^c Cambian Healthcare   (United Kingdom)

^d Cambian Healthcare   (United Kingdom)

Author keywords

global functioning; Psychosocial functioning; recovery; schizophrenia; symptoms

Indexed keywords

ADULT; AGE; AGING; ARTICLE; CAUCASIAN; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONGENITAL MALFORMATION; EXPOSURE; HISTORY; HOSPITALIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MEDICAL HISTORY; MENTAL DISEASE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; SAMPLE; SCHIZOPHRENIA; SENESCENCE; SOCIAL PSYCHOLOGY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGE OF ONSET; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 79751469145     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2010.519035     Document Type: Article

References (54)

1. Saha, S Chant, D Welham, J McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2(5):e141.
2. Ustun TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J, and the WHO/NIH Joint Project CAR Study Group. Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. Lancet 1999;10:111-15. (Pubitemid 29313145)
3. Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis 1996;184:653-9. (Pubitemid 27006435)
4. Kraepelin E. Psychiatry. A textbook for students and physicians, Vol 2. Canton: Science History Publications; 1899.
5. Harris MJ, Jeste VJ. Late-onset schizophrenia: An overview. Schizophr Bull 1988;14:39-55.
6. Castle DJ, Murray RM. The epidemiology of late-onset schizophrenia. Schizophr Bull 1993;19:691-700. (Pubitemid 23339427)
7. Ö ng ü r D, Lin L, Cohen BM. Clinical characteristics infl uencing age at onset in psychotic Disorders. Comp Psychiatry 2009;50:13-19.
8. Honga J, Windmeijerc F, Novickb D, Harod JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuro-Psychopharmacol Biol Psychiatry 2009;33:835-41.
9. Harrison G, Hopper K, Craig T, Laska E, Dube KC, Ganev C, et al. Recovery from psychotic illness: a 15-and 25-year international follow-up study. Br J Psychiatr 2001; 178:506-17. (Pubitemid 32531743)
10. Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatr 1980;136:413-20. (Pubitemid 10102998)
11. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 1987;144:727-35. (Pubitemid 17086851)
12. Mortimer A. Another triumph of hope over experience: Revisiting.. treatment of the patient with long-term schizophrenia. Adv Psychiatr Treat 2005;11:277-85. (Pubitemid 40946135)
13. Harvey PD, Howanitz JM, Parrella M, White L, Powchik P, Davidson M, et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatr 1999:45:32-40. (Pubitemid 29049202)
14. Sharma T, Harvey P. Cognition in schizophrenia: impairments: importance, and treatment strategies. Oxford: Oxford University Press; 2000.
15. Priebe S. Social outcomes in schizophrenia. Br J Psychiatry 2007;50(Suppl):15-20.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
17. Andreasen NC, Carpenter WT, Kane JM, Lasser SR et al., Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162: 441-9. (Pubitemid 40343909)
18. WHOQOL Group. The World Health Organization quality of life assessment (the WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995;41:1403-9.
19. Endicott J, Spitzer R, Fleiss J, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatr 1976;33:766-71.
20. Piersma HL, Boes JL. The GAF and psychiatric outcome: a descriptive report. Comm Men Health J 1997;33:35-40.
21. Moriearty P, Bogdanich R, Dexter N, et al. Incorporating results of a provider attitudes survey in development of an assessment program. Am J Med Quality 1999;14: 178-84.
22. Shea T. Core Battery Conference: Assessment of Change in Personality Disorders. Washington, DC: American Psycho-logical Association; 1997.
23. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatr 2004;161:473-9. (Pubitemid 38326102)
24. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8.
25. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC A ran-domised controlled trial of prophylactic neuroleptic treat-ment. Br J Psychiatry 1986;148:120-7. (Pubitemid 16158512)
26. Wyatt, RJ. Early intervention for schizophrenia: Can the course of the illness be altered? Biol Psychiatry 1995;38:1:1-3.
27. Buchsbaum MS, Hazlett E. Functional brain imaging and aging in schizophrenia Schizophr Res 1997;27:129-41. (Pubitemid 27512850)
28. Hietala J, Cannon TD, van Erp M, Syv ä lahti E, Vilkman H, Laakso A, et al. Regional brain morphology and duration of illness in never-medicated first-episode patients with schizophrenia. Schizophr Res 2003;64:79-81. (Pubitemid 37153352)
29. Ho B-C, Andreasen N, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome. A longitudinal mag-netic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003;60:585-94. (Pubitemid 36682316)
30. Goldstein PC, Brown GG, Marcus A, Ewing JR. Effects of age, neuropsychological impairment, and medication on regional cerebral blood fl ow in schizophrenia and major affective disorder. Henry Ford Hosp Med J 1990;38: 202-6.
31. Schultz SK, Daniel MD, O'Leary S, Boles-Ponto LL, Arndt S, Magnotta V, et al. Age and regional cerebral blood fl ow in schiz-ophrenia. J Neuropsychiatr Clin Neurosci 2002;14:19-24.
32. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatr 1996;153: 466-76. (Pubitemid 26113309)
33. Finch CE, Morgan DG. RNA and protein metabolism in the aging brain. Annu Rev Neurosci 1990;13:75-88. (Pubitemid 20100642)
34. Morgan DG, Marcusson JO, Nyberg P, Wester P, Winbald B, Gordon MN, et al. Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging. Neurobiol Aging 1987;3:195-201. (Pubitemid 17111020)
35. Harvey PD, Parella M, White L, Mohs RC, Davidson D, Davis KL. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res 1999;35:77-84. (Pubitemid 29023556)
36. Palmer BW, Bondi MW, Twamley EW, Thal M, Golshan S, Jeste DV. Late-onset schizophrenia spectrum disorders neu-rodegenerative conditions? Annual rates of change on two dementia measures. J Neuropsychiatr Clin Neurol 2003; 15:45-52. (Pubitemid 36168078)
37. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatr 1999;46:1396-408.
38. Zisook S, Heaton R, Moranville J, Kuck J, Jernigan T, Braff D. Past substance abuse and clinical course of schizophrenia. Am J Psychiatry 1992;149:552-3.
39. Hertz L. Is Alzheimer's disease anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells? Brain Res Rev 1989;4:335-53. (Pubitemid 20042044)
40. Cutler, D. Community residential options for the chronically mentally ill. Comm Men Health J 1986:22:61-73.
41. Kavanagh DJ. Recent developments in expressed emotion and schizophrenia. Br J Psychiatr 1992;160:601-20.
42. Dyck DG, Short RA, Hendry MS, et al. Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr Serv 2000;51: 513-19. (Pubitemid 30212095)
43. Pekkala E, Merinder L. Psychoeducation for schizophrenia (Cochrane Review). Cochrane Library 2001:4. Oxford: Update Software.
44. H ä fner H, Maurer K, Ruhrmann S, Bechdolf A, Klosterkotter J, Wagner M, et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatr Clin Neurol 2004; 254: 117-28.
45. Grossman LS, Harrow M, Rosen C, Faull R. Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatr Serv 2006;57: 844-50. (Pubitemid 43846297)
46. Usall J, Ochoa S, Araya S, M á rquez M, NEDES Group. Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. Eur Psychiatry 2003;6:282-84. (Pubitemid 37461919)
47. Piersma HL, Boes JL. The GAF and psychiatric outcome: a descriptive report. Comm Ment Health J 1997;33:35-40.
48. Goldman M, Dequardo JR, Tandon R, Taylor SF, Jibson M. Symptom correlates of global measures of severity in schizophrenia. Comp Psychiatry 1999;40:458-61.
49. Howes JL, Haworth H, Reynolds P, et al. Outcome evaluation of a short-term mental health day treatment program. Can J Psychiatry 1997;42:502-8. (Pubitemid 27298737)
50. Phelan M, Wykes T, Goldman H. Global function scales. Soc Psychiatry Psychiatr Epidemiol 1994;29:205-11. (Pubitemid 24283721)
51. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-59.
52. Moos RH, McCoy L, Moos BS. Global Assessment of Functioning (GAF) ratings: determinants and role as predictors of one year treatment outcomes. J Clin Psychol 2000;56:449-61. (Pubitemid 30196646)
53. Roy-Byrne P, Dagadakis C, Unutzer J, Ries R. Evidence for limited validity of the revised Global Assessment of Functioning Scale. Psychiatr Ser 1996;47:864-6. (Pubitemid 26264740)
54. Schorre BEH, Vandvik IH. Global assessment of psychosocial functioning in child and adolescent psychiatry: a review of three unidimensional scales (CGAS, GAF, GAPD). Eur Child Adolesc Psychiatry 2004;13:273-86. (Pubitemid 39390319)